Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Liposomal Amphotericin B for Injection in Healthy Chinese Subjects
NCT06983665Completed
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- May 2025
- Primary completion
- Nov 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of liposomal amphotericin b in invasive fungal infection (IFI), neutropenic fever and visceral leishmaniasis (VL) (2 arms), sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration of Liposome-Encapsulated Amphotericin B, Area Under the Curve from Time Zero to Last Quantifiable Concentration of Liposome-Encapsulated Amphotericin B and 1 more. Started May 2025; status: completed.
02
Drugs
liposomal amphotericin b
03
Conditions
invasive fungal infection (IFI)neutropenic fevervisceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT06983665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06983665.